A hot (if cautious) topic at the big gene therapy meeting: what Vinay Prasad's appointment might mean for approvals in rare ...

At the American Society of Cell and Gene Therapy conference, there were questions and qualms on how Vinay Prasad may change ...

The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...

Not Vinay Prasad. The new top regulator of vaccines and gene therapies at the Food and Drug Administration has never shied ...

Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

Vinay Prasad, MD, MPH, a frequent critic of the FDA and COVID-19 lockdowns and vaccination policies, will be the next ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was forced out.

Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...